Bavarian Nordic Accelerates Ebola Vaccine Development Programmes in Collaboration with NIH
Bavarian Nordic will accelerate its collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), on the development of its Ebola vaccine programmes. Bavarian Nordic and partners are planning to initiate the first trial of a promising combination vaccine regimen in humans in 2015.
Bavarian Nordic has worked with NIAID for several years to advance its MVA-BN technology to develop a combined vaccine against Ebola and Marburg viruses, both of which are high-priority biological agents. A recent study, conducted under NIAID's vaccine preclinical services program, demonstrated proof of concept for a prime-boost regimen of two vaccines based on Bavarian Nordic's MVA-BN technology and Crucell's (part of the Janssen Pharmaceutical companies of Johnson & Johnson) AdVac technology respectively. Results from the study show complete protection against the highly virulent Ebola Zaire species, which is responsible for the current outbreak in West Africa. Planning is ongoing to accelerate the development of this combination vaccine regimen with the initiation of a trial in humans, anticipated in 2015.
Bavarian Nordic is concurrently developing additional Ebola vaccine candidates, which are in preclinical testing. Among these candidates is a multivalent vaccine that protects against the two major strains of Ebola (Zaire and Sudan) as well as Marburg. The Company is also in discussions with the NIAID to accelerate the development of this multivalent vaccine into a clinical Phase I study in the next 12 months.
Paul Chaplin, PhD, President and CEO of Bavarian Nordic stated: "Given the current global health crisis affecting West Africa and beyond, there is a clear need for efficacious protection and treatment against highly lethal infections like Ebola. The World Health Organization has warned that the outbreak now constitutes an international health risk, so this joint effort between Bavarian Nordic, Crucell and NIH is an important example of government agencies and private entities collaborating to address potential global threats. In our contribution to the development of a potential new Ebola vaccine, we leverage our expertise in the development and manufacturing of smallpox vaccines, which we have supplied to the US Government since 2010."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance